Overview
Boston Scientific's neuromodulation portfolio spans spinal cord stimulation, deep brain stimulation, and sacral neuromodulation for pain, movement disorders, and pelvic conditions. Their Vercise Genus DBS system and WaveWriter Alpha SCS platform represent the company's latest advances in closed-loop, personalized neural therapy.
More in Neuromodulation
Latest industry news
FDA Grants De Novo Approval to Modius Spero, Clearing First Neuromodulation Device for PTSD
2026-09-03 · Policy
Butterfly Network's BCI Chip Licensing Deal Rattles Investors as Shares Drop Nearly 10%
2026-09-02 · Industry
Merge Labs and Butterfly Network Unite to Push Ultrasound-Based BCIs Into the Mainstream
2026-09-01 · Industry
FDA Grants CorTec Second Breakthrough Device Designation for Its Brain-Computer Interface
2026-08-31 · Policy
Company details
Category
⚡ Neuromodulation
Location
Marlborough, MA, USA
Funding
NYSE: BSX
Listed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →